Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
An observational study of patients with cystic fibrosis (CF) starting treatment with Kaftrio (Elexacaftor / Tezacaftor / Ivacaftor) as part of routine clinical care, following EMA licensing (approved end of Aug 2020). - Patients with CF who are p.Phe508del homozygotes will already be receiving the less effective CFTR modulator drug Symkevi (Tezacaftor / Ivacaftor) and will switch to KaftrioTM. - Patients who are who are compound heterozygotes for p.Phe508del / minimal function mutation currently have access to no effective CFTR modulator and will be starting a CFTR modulator (Kaftrio) for the first time. Participants attend a study visit before Kaftrio treatment commences, followed by visits at 12 and 24 weeks after starting treatment. At each visit they will be scanned before and after standardised meals in the morning and mid-day (11 scans in total over 6 hours). No intravenous contrast or bowel preparation will be used. Participants will complete questionnaires on gastrointestinal symptoms as well as providing stool and sputum samples for assessment of microbiome and stool for inflammatory mediators and pancreatic function (elastase).
Description: the time when the test meal is first detectable in the caecum
Measure: Difference in oro-caecal transit time (OCTT) in minutes at baseline and 24 weeks Time: 3 days of scanningDescription: A measure of small bowel water representing secretions
Measure: Small bowel water content (SBWC) area under the curve (AUC), corrected for body surface area, measured in L.min/m^2 between 0 and 360 minutes at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: These are small bowel water measurements before and after the second test meal
Measure: Change in SBWC between 240 and 300 minutes (delta DTI) at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: volume of colon representing ease of chyme passage through colon
Measure: Colonic volume area under the curve (AUC), corrected for body surface area at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of gut inflammation
Measure: Stool calprotectin at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of types of microbiome present in the stool and sputum
Measure: Stool and sputum microbiome at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A marker of pancreatic exocrine function
Measure: Stool elastase at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of motility at the terminal ileum using the GIQuant tool in arbitrary units
Measure: Terminal ileum motility at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of gut symptoms over the preceding 2 weeks and during the study day
Measure: Abdominal symptoms as measured by the CFAbd-Score Time: 3 days of scanningDescription: A measure of gut symptoms over the preceding 2 weeks and during the study day
Measure: Abdominal symptoms as measured by the PAC-SYM score Time: 3 days of scanningDescription: A measure of gut symptoms over the preceding 2 weeks and during the study day
Measure: Abdominal symptoms as measured by 3 domains from the Gastrointestinal Symptoms Rating Scale (GSRS) Time: 3 days of scanningDescription: A measure of lung function
Measure: Spirometry (FEV1) at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of body mass
Measure: Weight (kg) at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of growth
Measure: Height (m) at baseline, 12 weeks and 24 weeks Time: 3 days of scanningAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports